• Eric P Sorensen and M Laurin Council.
• Both authors are affiliated with the Division of Dermatology, Washington University in St. Louis, Saint Louis, Missouri.
• Dermatol Surg. 2020 May 1; 46 (5): 671-677.

BackgroundSoft-tissue filler administration is an increasingly popular minimally invasive cosmetic procedure. Simultaneously, there have been a greater number of adverse events reported, including the devastating complication of blindness.ObjectiveTo report cases of filler-related blindness published since 2015.Materials And MethodsThe Ovid MEDLINE database was searched from January 1, 2015, to August 1, 2018, using a previously described Boolean string.ResultsSixty new cases of filler blindness were identified. The most common type of filler reported was hyaluronic acid (HA) (N = 42, 70.0%), followed by autologous fat (N = 7, 11.7%), and calcium hydroxyapatite (CaHA) (N = 7, 11.7%). The most common injection locations were the nose (N = 33, 55.0%), glabella (N = 21, 35.0%), and forehead (N = 11, 18.3%). Ten cases reported vision restoration (16.7%). Four of the successful cases involved hyaluronidase administration, including 1 retrobulbar hyaluronidase injection.ConclusionSince 2015, there have been 60 newly reported cases of soft-tissue filler blindness. Most recent cases have occurred with HA, which is a shift from previous reports. In HA cases, hyaluronidase injection may be successful in restoring vision if administered promptly. It is imperative for providers to be familiar with strategies for managing soft-tissue filler blindness.

14 keywords...

hide…